Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Toyota Global Sales Fall as China Demand Slumps 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
CIA-Linked Investor Helped Quantum Systems Expand in US 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Street Poller Media and The Boom of the Street Interview Ad Industry 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Add as a preferred source on Google
NEW YORK, April 02, 2018 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the enhancement of its Healthcare Equity Research practice with the promotion of Dr. Jason McCarthy, Ph.D. to Senior Managing Director of Biotechnology.
“Maxim Group continues to build one of the premier proprietary research platforms on Wall Street, with an emphasis on emerging growth and paradigm-shifting businesses. Biotechnology is an important vertical in our healthcare practice and we are proud to have Jason leading this effort,” said Anthony V. Vendetti, Executive Managing Director of Research for Maxim Group. The biotechnology team currently covers over 50 research names and expects to double research coverage over the next year as more resources are added to build out this important vertical.
In his expanded role, Dr. McCarthy will work with Anthony Vendetti in the development and implementation of Maxim Group’s biotechnology research strategy with a key focus on product expansion on the Institutional and Wealth Management platforms. Dr. McCarthy received his doctoral degree in Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University.
Michael Rabinowitz, Chairman & CEO of Maxim Group, added “Our commitment to build a first class healthcare practice has never wavered, and Dr. McCarthy’s well-deserved promotion is another significant step in that process. As we continue our firm-wide expansion, we expect to add other high quality professionals to the Maxim Group Research team.”
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
[email protected]
